Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $15.36B in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 435.86B 8.73B Aug/2026
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
ALKERMES USD 7.93B 806M Aug/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 209.65B 14.21B Aug/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.71B 651M Aug/2026
Cytokinetics USD 9.6B 1.95B Aug/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 15.27B 1.73B Aug/2026
Gilead Sciences USD 168.68B 11.82B Aug/2026
Halozyme Therapeutics USD 10.91B 1.63B Aug/2026
Incyte USD 26.84B 4.19B Aug/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Nektar Therapeutics USD 12.98B 10.86B Aug/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pfizer USD 153.17B 14.73B Aug/2026
Prothena USD 516M 2M Mar/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Repligen USD 7.86B 168M Aug/2026
Sarepta Therapeutics USD 1.5B 402M Aug/2026
Teva Pharmaceutical Industries USD 114.54B 80.27B Jun/2026
Ultragenyx Pharmaceutical USD 2.12B 1.16B Aug/2026
Vertex Pharmaceuticals USD 137.33B 11.26B Aug/2026